Fernando Bril MDAssistant Professor, Division of Endocrinology, Diabetes and Metabolism, Division of Internal Medicine, Department of Medicine, University of Florida, Gainesville, Florida
Even before starting his Internal Medicine residency, Dr. Bril had a strong interest in clinical research and biostatistics, embarking early-on on a career as a physician-scientist. He joined the Division of Endocrinology, Diabetes and Metabolism at the University of Florida in Gainesville, Florida, in 2012 as a Post-Doctoral Associate. Later, Dr. Bril stayed as a faculty member, first as an Assistant Scientist, and subsequently as an Assistant Professor.
Dr. Bril’s main research interest has been to understand the metabolic mechanisms that promote the progression from isolated steatosis to NASH and to identify pharmacological approaches that could be used to delay this progression. His research group has carried out several clinical and translational research studies that have resulted in significant peer-reviewed articles in the field, including 2 randomized controlled trials on the use of pioglitazone alone or combined with vitamin E (Cusi, et al. Annals Intern Med 2016; Bril, et al Diabetes Care 2019). More specifically, in the last few years, they have carefully examined how the severity of liver disease influences changes in dyslipidemia, diabetes control, and insulin resistance, all mechanisms potentially leading to this increased cardiovascular risk in patients with NAFLD (Bril, et al. Hepatology 2017; Bril, et al J Clin Endocrinol Metab 2016; Bril, et al. Hepatology 2014). Dr. Bril and his research group have also focused on the assessment of potential new plasma and imaging biomarkers for the diagnosis of NAFLD (Bril, et al. Diabetes Care 2019; Bril, et al. Diabetes Obes Metab 2018; Bril, et al. Liver Int 2015; Bril, et al J Hepatol 2015).